Binding and antiresorptive properties of heterocycle-containing bisphosphonate analogs: Structure-activity relationships

Bone

Volumn 23, Issue 5, 1998, Pages 437-442

  Van Beek, E R ^a   Lowik C W G M ^a   Ebetino, F H ^b   Papapoulos, S E ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

Author keywords

Bisphosphonates; Bone cultures; Bone resorption; Mineralization; Risedronate

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; ETIDRONIC ACID; NE 10575; NE 10970; NE 58018; NE 58051; NE 58066; RISEDRONIC ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BONE MINERAL; CONTROLLED STUDY; DRUG ACTIVITY; EXPERIMENTAL MODEL; FEMALE; IN VITRO STUDY; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; STRUCTURE ACTIVITY RELATION;

ALENDRONATE; ANIMALS; BONE AND BONES; BONE RESORPTION; CALCIFICATION, PHYSIOLOGIC; CALCIUM; CULTURE TECHNIQUES; ETIDRONIC ACID; FEMALE; MICE; PREGNANCY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0344074580     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S8756-3282(98)00120-3     Document Type: Article

References (22)

1. Benedict J.J. The physical chemistry of the disphosphonates - its relationship to their medical activity. Donath A., Courvoisier B. Disphosphonates and Bone Symposium CEMO IV, Nyon, Switzerland . 1982;1-19 Editions Medecine et Hygiene, Geneva.
2. Brown R.J., van Beek E., Watts D.J., Löwik C.W.G.M., Papapoulos S.E. Differential effects of aminosubstituted analogs of hydroxy bisphosphonates on the growth of Dictyostelium discoideum. J Bone Miner Res. 13:1998;253-258.
3. Burger E.H., van der Meer J.W.M., van de Gevel J.S., Gribnau J.C., Thesingh C.W., van Furth R. In vitro formation of osteoclasts from long-term cultures of bone marrow mononuclear phagocytes. J Exp Med. 156:1982;1604-1615.
4. Ebetino, F. H., Bayless, A. V., Amburgey, J., Ibbotson, K. J., Dansereau, S., and Ebrahimpour, A. Elucidation of a pharmacophore for the bisphosphonate mechanism of bone antiresorptive activity. Phosphorus, sulfur, and silicon 109-110:217-220; 1996.
5. Ebrahimpour A., Francis M.D. Bisphosphonate therapy in acute and chronic bone loss Physical chemical considerations in bisphosphonate-related therapies . Bijvoet O.L.M., Fleisch H.A., Canfield R.E., Russel R.G.G. Bisphosphonate on Bones. 1995;126-137 Elsevier, Amsterdam.
6. Fleisch H. Bisphosphonates Pharmacology and use in the treatment of tumor-induced hypercalcemic and metastatic bone disease . Drugs. 42:1991;919-944.
7. Geddes A.D., D'Souza S.M., Ebetino F.H., Ibbotson K.J. Bisphosphonates Structure-activity relationships and therapeutic implications . Heersche J.N.M., Kanis J.A. Bone Mineral Research. Vol. 8:1994;265-306 Elsevier, Amsterdam.
8. Ibbotson K.J., D'Souza S.M., Bayless A., Ebrahimpour A., Ebetino F.H., Woodiel F.N., Fall P.E., Raisz L.G. The phosphonate moieties of bisphosphonates are more than just a targeting function Evidence from the study of bisphosphonate analogues in vitro . Bone Miner. 25:(Suppl. 1):1994;S66.
9. Jung A., Bisaz S., Fleisch H. The binding of pyrophosphate and two diphosphonates on hydroxyapatite crystals. Calcif Tissue Res. 11:1973;269-280.
10. Klein-Nulend J., Veldhuizen J.P., Burger E.H. Increased calcification of growth plate cartilage as a result of compressive force in vitro. Arthr Rheum. 29:1986;1002-1009.
11. Lin J.H. Bisphosphonates A review of their pharmacokinetic properties . Bone. 18:1996;75-85.
12. Papapoulos S.E. Bisphosphonates Pharmacology and the use in the treatment of osteoporosis . Marcus R., Feldman D., Kelsey J. Osteoporosis. 1996;1209-1234 Academic, San Diego; CA.
13. Papapoulos S.E. Pharmacodynamics of bisphosphonates in man; implications for treatment. Bijvoet O.L.M., Fleisch H.A., Canfield R.E., Russel R.G.G. Bisphosphonate on Bones. 1995;231-245 Elsevier, Amsterdam.
14. Rogers J., Xiong X., Brown R.J., Watts D.J., Russel G.G., Bayless A.V., Ebetino F.H. Structure-activity relationships of new hetrocycle-containing bisphosphonates as inhibitors of bone resorption and as inhibitors of growth of Dictyostelium discoideum amoeba. Mol Pharmacol. 47:1995;398-402.
15. Rogers M.J., Watts D.J., Russel G.G., Xiaohuil J.I., Xiong X., Blackburn G.M., Bayless A.V., Ebetino F. Inhibitory effects of bisphosphonates on growth of amoebae of the cellular slime mold Dictyostelium discoideum. J Bone Miner Res. 9:1994;1029-1039.
16. Shinoda H., Adamek G., Felix R., Fleisch H., Schenk R., Hagan P. Structure-activity relationships of various bisphosphonates. Calcif Tissue Int. 35:1983;87-99.
17. Sietsema W.K., Ebetino F.H., Salvagno A.M., Bevan J.A. Antiresorptive dose-response relationships across three generations of bisphosphonates. Drugs Exp Clin Res. 15:1989;389-396.
18. Sunberg R., Ebetino F.H., Mosher C.T., Roof C.F. Designing drugs for stronger bones. Chemtech. 21:1991;304-309.
19. van Beek E., Hoekstra M., van de Ruit M., Löwik C., Papapoulos S. Structural requirements for bisphosphonate actions in vitro. J Bone Miner Res. 9:1994;1875-1882.
20. van Beek E., Löwik C., Oue I., Papapoulos S. Dissociation of binding and antiresorptive properties of hydroxybisphosphonates by substitution of the hydroxyl with an amino group. J Bone Miner Res. 11:1996;1492-1497.
21. van Beek E., van der Wee-Pals L., van de Ruit M., Nijweide P., Papapoulos S., Löwik C. Leukemia inhibitory factor inhibits osteoclastic resorption, growth, mineralization, and alkaline phosphatase activity in fetal mouse metacarpal bones in culture. J Bone Miner Res. 8:1993;191-197.
22. van der Pluijm G., Most W., van der Wee-Pals L., de Groot H., Papapoulos S., Löwik C. Two distinct effects of recombinant human tumor necrosis factor-α on osteoclast development and subsequent resorption of mineralized matrix. Endocrinology. 129:1991;1596-1604.